Drug Profile
Research programme: potassium channel antagonists - Predix Pharmaceuticals
Latest Information Update: 28 Mar 2008
Price :
$50
*
At a glance
- Originator EPIX Pharmaceuticals
- Class
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atrial fibrillation; Brugada syndrome
Most Recent Events
- 17 Aug 2006 Predix Pharmaceuticals has been acquired and merged into EPIX Pharmaceuticals
- 04 Apr 2006 No development reported - Preclinical for Brugada syndrome in USA (unspecified route)
- 27 Mar 2006 Preclinical trials in Atrial fibrillation in USA (unspecified route)